Annovis Bio

Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials

MALVERN, PA — In a recent financial report for 2023, Annovis Bio, Inc. (NYSE: ANVS) proclaimed progress in the battle against neurodegenerative diseases; however, the path to potential breakthroughs has …

Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials Read More

Virpax Pharmaceuticals

Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions

BERWYN, PA — Recent developments have been flourishing for Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX). The Pennsylvania-based pharmaceutical innovator recently unveiled its financial records for 2023 and shared a series of …

Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions Read More